Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, who spotlighted agents that are currently used for the treatment of RET fusion–positive thyroid cancer. Although only a subset of patients with papillary thyroid cancer have disease that is driven by RET fusions, over half of all patients with medullary disease have RET mutations. Due to this, RET is believed to play an important role in the treatment of thyroid cancer
Transcript:
One of the things that we knew about for a long time is that a subset of thyroid cancers are driven by RET fusion genes [in papillary disease]. For medullary [disease], on other hand, probably about 55% or 60% are driven by RET mutations, either hereditary or somatic. We know RET plays a very important role in the treatment of thyroid cancers. A lot of the treatments that started out for medullary thyroid cancer were really based on the fact that certain drugs like cabozantinib [Cabometyx] and vandetanib [Caprelsa] targeted RET. Because of that, although these drugs hit many different targets, pretty good activity was seen and both vandetanib and cabozantinib got FDA approvals. [However], other drugs like sunitinib [Sutent], pazopanib [Votrient], and lenvatinib [Lenvima] were also shown to have reasonable activity, although they never went through randomized phase 3 studies.
Reference
Sherman EJ, Wirth LJ, Shah MH, et al. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: a clinical trial update. J Clin Oncol. 2021;39(suppl 15):6073. doi:10.1200/JCO.2021.39.15_suppl.6073
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.